Media Resources

2015

Health Action International Launches New Brussels Office

Health Action International Criticises JURI Support for EU Trade Secrets Directive Report

How TTIP Could Damage Access to Affordable Medicines in the European Union

Assessing the Nature, Extent and Impact of Regulation of Medicines Promotion

2014 Annual Report and Financial Statements

2014 Annual Report and Financial Statements

EU Clinical Trials Regulation: EMA Steers Away from Transparency by Misinterpreting Exception Provisions

2014

Retention of Medicines Policy in DG Health a Victory for Public Health Advocates

EMA’s Final Policy on Access to Clinical Data: Proactive Access to Some Data, But Strings Attached

EU Pharmacovigilance Public Hearings Should Be As Transparent and Independent as in US

Trading Away Access to Medicines – Revisited

Europe Seeks to Expand Big Pharma Monopoly at Expense of Poor People, Warn NGOs Ahead of TTIP Talks (2014)

Public Health in Danger with Move of Pharmaceutical Policy to DG Enterprise and Industry

Mapping External Reference Pricing Practices for Medicines

Investor-State Dispute Settlement in EU-US Trade Deal Risks Access to Affordable Medicines

EMA’s New Policy on Access to Clinical Data – About to Privatise Pharmaceutical Knowledge?

Health Action International Welcomes Adoption of New Clinical Trials Regulation by European Parliament

Health Action International Applauds Medicines Patent Pool, ViiV Healthcare Licensing Agreement for New HIV Treatment

The EU-US Trade Agreement – Proposals by Pharmaceutical Industry Undermine European Public Policymaking and Public Health

EU Regulation on Clinical Trials – Close to the Finish Line

2013 Annual Report and Financial Statements

2013 Annual Report and Financial Statements

Working Paper 4 – Competition Policy

Policy Brief 3 – Regulation of Mark-ups in the Pharmaceutical Supply Chain

Policy Brief 5 – Sales Taxes on Medicines

Policy Brief 2 – The Role of Health Insurance in the Cost-effective Use of Medicines

Working Paper 1 – External Reference Pricing

Policy Brief 4 – Competition Policy

Policy Brief 1 – External Reference Pricing

Working Paper 2 – The Role of Health Insurance in the Cost-Effective Use of Medicines